NVO
A judge just swatted the spray
Novo Nordisk got a legal W on Wednesday when a District Court in The Hague issued a preliminary injunction against Ceban Ziekenhuisfarmacie B.V., ordering it to stop selling an unauthorized semaglutide nasal spray immediately. In plain English: the court said, “Nice try, but no.”
Why investors should care
This isn’t just about one pharmacy’s product page getting taken down. The ruling protects Novo’s supplementary protection certificate for semaglutide, the ingredient behind Wegovy, Ozempic, and Rybelsus. That matters because the GLP-1 market is basically the Super Bowl of pharma right now, and Novo has been fighting to keep knockoff or unauthorized versions from muddying the waters.
The court didn’t stop at ‘please desist’
The injunction reportedly requires Ceban to:
- stop all infringing sales right away
- remove references to the product from websites and listings
- hand over details on its supply chain
- reimburse Novo’s legal costs
That’s not a slap on the wrist. That’s the legal equivalent of getting sent to your room and asked to explain who gave you the keys in the first place.
The bigger GLP-1 brawl
Novo is also in the middle of a separate U.S. fight with Eli Lilly, which it sued in July over alleged deceptive marketing tied to Zepbound and Mounjaro. So while this Dutch case is about semaglutide IP and an unauthorized compounded product, it fits the same bigger story: Novo is building a moat around a wildly valuable drug class.
Big picture: if you own NVO, this is the kind of legal win that helps defend pricing power, brand control, and the long-term value of the GLP-1 machine.